Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
Chengdu, CN
Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research, development, and distribution of vaccines. Their current product portfolio includes immunizations against tetanus, a severe and often fatal infectious disease that damages the nervous system due to toxins produced by Clostridium tetani, alongside a vaccine for Haemophilus influenzae type b. Beyond their existing offerings, the company is actively advancing new vaccine candidates targeting Staphylococcus aureus, a prevalent bacterium responsible for both hospital-acquired and community infections, and illnesses associated with Group A streptococcus. This enterprise was established in 2009 and operates from its base in Chengdu, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.35% | -6.27% | +13.83% | +27.82% | +36.24% | +38.60% | +92.81% | +61.16% | -11.90% | -11.90% | -11.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+19.6% ★ Q1'26: +80.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+7.0% Q1'26: +485.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+1.0% Q1'26: -30.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+4.5% ★ Q1'26: +20.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.2% ★ Q1'26: +9.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×6.03× Q1'26: 3.35× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
487.15M
est: 501.33M (-2.8%)
|
547.48M
est: 547.48M (+0.0%)
|
496.12M
est: 489.20M (+1.4%)
|
588.86M
est: 583.00M (+1.0%)
|
704.16M
est: 690.71M (+1.9%)
|
735.29M
735.29M – 735.29M
+6.5% YoY
|
786.27M
786.27M – 786.27M
+6.9% YoY
|
977.89M
977.89M – 977.89M
+24.4% YoY
|
1.48B
1.48B – 1.48B
+51.1% YoY
|
1.83B
1.83B – 1.83B
+23.7% YoY
|
| EBITDA |
131.59M
est: 60.30M (+118.2%)
|
74.11M
est: 65.85M (+12.5%)
|
49.96M
est: 68.60M (-27.2%)
|
64.78M
est: 81.76M (-20.8%)
|
59.85M
est: 96.86M (-38.2%)
|
103.11M
103.11M – 103.11M
+6.5% YoY
|
110.26M
110.26M – 110.26M
+6.9% YoY
|
137.13M
137.13M – 137.13M
+24.4% YoY
|
207.15M
207.15M – 207.15M
+51.1% YoY
|
256.24M
256.24M – 256.24M
+23.7% YoY
|
| EBIT |
108.55M
est: 35.17M (+208.7%)
|
48.81M
est: 38.41M (+27.1%)
|
22.85M
est: 45.58M (-49.9%)
|
36.83M
est: 54.32M (-32.2%)
|
31.89M
est: 64.36M (-50.4%)
|
68.51M
68.51M – 68.51M
+6.5% YoY
|
73.26M
73.26M – 73.26M
+6.9% YoY
|
91.11M
91.11M – 91.11M
+24.4% YoY
|
137.63M
137.63M – 137.63M
+51.1% YoY
|
170.25M
170.25M – 170.25M
+23.7% YoY
|
| Net Income |
107.96M
est: 114.80M (-6.0%)
|
26.58M
est: 28.36M (-6.3%)
|
17.56M
est: -38.95M (+145.1%)
|
20.76M
est: 48.68M (-57.4%)
|
22.23M
est: 43.81M (-49.3%)
|
34.48M
34.48M – 34.48M
-21.3% YoY
|
46.65M
46.65M – 46.65M
+35.3% YoY
|
77.08M
77.08M – 77.08M
+65.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
296.33M
est: 329.78M (-10.1%)
|
352.06M
est: 360.13M (-2.2%)
|
336.12M
est: 299.39M (+12.3%)
|
389.32M
est: 356.80M (+9.1%)
|
330.99M
est: 422.72M (-21.7%)
|
450.00M
450.00M – 450.00M
+6.5% YoY
|
481.20M
481.20M – 481.20M
+6.9% YoY
|
598.48M
598.48M – 598.48M
+24.4% YoY
|
904.04M
904.04M – 904.04M
+51.1% YoY
|
1.12B
1.12B – 1.12B
+23.7% YoY
|
| EPS |
0.28
est: 0.28 (-1.2%)
|
0.07
est: 0.07 (-6.3%)
|
0.04
est: -0.10 (+145.1%)
|
0.05
est: 0.12 (-57.3%)
|
0.05
est: 0.11 (-49.3%)
|
0.09
0.09 – 0.09
-21.3% YoY
|
0.12
0.12 – 0.12
+35.3% YoY
|
0.19
0.19 – 0.19
+65.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aimin Chen | Director & Deputy GM | — | female |
| Shaowen Fan | Chairman of the Board & GM | — | male |
| Wei Wu | Secretary of the Board & Deputy GM | — | male |
| Xingyao Qin | Accounting supervisor | — | male |
| Yong Tan | Chief Financial Officer & Deputy GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688319.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
